PubMed · 15134289
PT-141 Palatin.
Abstract
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Petter Hedlund. 2004. PT-141 Palatin.. https://pubmed.ncbi.nlm.nih.gov/15134289/
Cite the original work for its findings. Save a collection to share your selection of sources.